Research found that KLK6 overexpression induces HMGA2 expression in colon cancer cells, contributing to CRC progression and metastasis. High KLK6 scores were linked to disease recurrence, suggesting its potential role as a biomarker.
The assay has a clinically relevant 5-day turnaround time and can be conducted on as little as 20 ng genomic DNA. It requires minimum input of tumor DNA without the need for matched normal and is histology agnostic, addressing pre-analytical variability.
Researchers identified high levels of circularized E7 RNA as a positive prognostic marker in anal squamous cell carcinoma (ASCC). The study suggests that circ E7 may play a role in HPV-driven cancers, including head and neck squamous cell carcinomas.
The study found that all tested tyrosine kinase inhibitors increased COX-2 expression in at least one of the tested cell lines in vitro. Fluorocoxib A uptake correlated with COX-2 expression detected by immunohistochemistry and Western blot analysis in xenografts in vivo.
Quinacrine repurposed with cisplatin synergizes to reduce cancer growth, increasing median time to tumor volume by 12 days; enhances apoptosis and inhibits autophagy in HNSCC cells.
The RESILIENT trial found disease control in 114 out of 126 patients evaluable per protocol and progression-free survival. The study suggests that label-agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefits for patients with relapsed refractory metastatic malignancies.
Researchers found that mutation and loss of TSC1 leads to decreased sensitivity to Hsp90 inhibitors, causing hypoacetylation of Hsp90. Co-targeting HDACs may restore Hsp90 acetylation and sensitivity in bladder cancer patients with TSC1 mutations.
The 2019 Nobel Prize has been awarded to William G. Kaelin Jr, Gregg L. Semenza, and Sir Peter J. Ratcliffe for their discoveries of how cells sense and adapt to oxygen availability. This mechanism has far-reaching implications for treating conditions like cancer, heart attack, and stroke.
Researchers have identified FGFR3 mutations in a subset of meningioma patients with favorable prognoses, suggesting potential for targeted therapy. These mutations may enhance diagnostic accuracy and clinical decision-making.
Targeting HDAC2 with romidepsin inhibits MDM2 expression and promotes apoptosis in dedifferentiated liposarcoma. This approach may offer a new therapeutic avenue for treating this aggressive tumor type.
The study found that HIV-1 Tat protein expression leads to perturbations in the human cellular proteome, affecting gene expression and cellular processes. This has significant implications for understanding HIV-1 latency reversal and potential therapeutic strategies.
Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2. Alteration in transcription and enhancer landscape occurs during disease progression, offering a potent therapeutic mark for targeting cancer cells.
Research reveals ONC201 induces cell death through mitochondrial stress mechanisms, independent of TRAIL transcription. The compound inhibits mitochondrial respiration and reduces DNA copy number, leading to ATP depletion and cell death.
Research findings show that PD-L1 expression facilitates immune escape in medulloblastoma patients. The study identifies subgroup-specific variations in PD-L1 expression and its relationship with therapeutic responses. Immune adjuvant therapies may be necessary to fully realize the benefits of PD-1 blockade treatments.
The study shows that ST1-ADC selectively inhibits tumor cell proliferation and induces tumor cell death in both in vitro and in vivo ovarian cancer models. The data provide promising results for the development of new therapeutic options to treat ovarian cancer.
Researchers developed a quantitative pharmacodynamic assay for detecting apoptosis in fixed tumor tissue, resolving limitations of existing methods. The assay uses colocalization of γH2AX and cleaved caspase-3 markers to identify apoptotic cells with high accuracy.
A peer-reviewed study published in Oncotarget found that OncoDNA's comprehensive testing and analysis services, combining multiple biomarkers, increased oncologists' ability to make informed treatment decisions. The study showed a significant improvement in overall survival for late-stage patients, from six months to over 12 months.
The study reveals a tendency for duplication in the 9p21.3 sequence associated with coronary artery disease, which may affect predisposition to CAD. Sequence analysis shows varied repeats with 10-15 SNPs between each other and 82 SNPs between the human genome sequence.
Precision oncology uses advanced molecular diagnostic technologies to select targeted therapies, resulting in improved overall survival and lower average total healthcare costs. Average weekly costs were significantly lower for the targeted treatment group compared to the control group.
Researchers develop therapeutic antibodies targeting the C-terminus of Sonic hedgehog, a protein involved in tissue homeostasis and repair. These antibodies show promise in inhibiting cancer cell growth and tumor formation in preclinical models.
Research highlights the importance of preserving healthy kidney tissue and minimizing ischemia time in partial nephrectomy to prevent chronic kidney disease. Minimally invasive surgery is also shown to offer therapeutic scope without compromising oncological outcomes.
Researchers found elevated mir-24-3p in breast cancer patients destined to metastasize despite best available therapy. High expression of mir-24-3p correlated with poor survival rate and specific gene expression signature in TCGA.
Researchers propose a new conceptualization of cancer based on physical and biophysical symmetry. The study suggests that understanding cancer through the framework of symmetry can help reveal new ways to understand cancer.
A recent study published in Oncotarget found that cancer drug affordability is correlated with wealth, with the US having the highest average monthly price per patented drug. This has led to a financial burden on both society and patients, with individuals diagnosed with cancer being 2.7 times more likely to declare bankruptcy.
A study published in Oncotarget identifies a key step in the modification of Snail1, which can alter its structure and function to promote prostate cancer cell migration. The researchers found that preventing this modification can abolish the migratory and invasive properties of human prostate cancer cells.
Researchers at Harvard Medical School have discovered a novel therapeutic strategy to treat drug-resistant thyroid cancers by combining vemurafenib with palbociclib, a CDK4/6 inhibitor. The treatment was shown to induce stronger cell death than when used alone, offering new hope for patients with papillary thyroid carcinoma.
Oncotarget has increased its publishing frequency to two issues per week, making scientific results widely available through various indexes and archives. This move aims to accelerate indexing processes and provide rapid access to medical researchers, practitioners, and the general public.
Four biomedical researchers from Aligarh Muslim University, National Institute of Immunology India, and University of Torino presented groundbreaking studies on kidney cancer treatment, chemoresistance, and asbestos-related tumors at FCS 2017. Oncotarget's travel grants enabled their participation in the conference.
Researchers have identified a potential therapeutic target for aggressive breast cancer cells lacking estrogen receptor alpha, but expressing estrogen receptor beta. Estrogen or estrogen-like chemicals can slow tumor growth and even cause regression in these cells, which could lead to new treatment options.